PRIMARY PREVENTION OF CERVICAL CANCER: PROGRESS AND PROSPECTS


Cite item

Full Text

Abstract

Today, unconditional role of papillomaviruses in the development of cervical cancer and other malignancies of urogenital tract is proved. Development of vaccines against papillomaviruses opens up new possibilities for prevention of diseases associated with this pathogen. The vaccination program against human papilloma virus is also an opportunity to strengthen the preventive measures against sexually transmitted infections in general.

References

  1. Прилепская В.Н. Профилактика рака шейки матки. Гинекология. 2007. Т. 9. № 1. С. 12-18.
  2. Прилепская В.Н., Роговская С.И., Бебнева Т.Н. и др. Тактика ведения пациенток с интраэпителиальной неоплазией шейки матки низкой степени // Акушерство и гинекология. 2008. С. 23-26.
  3. Бебнева Т.Н., Прилепская В.Н. Папилломавирусная инфекция и патология шейки матки. Гинекология. 2007. Т. 3. № 3. С. 77-81.
  4. Профилактика рака шейки матки. Руководство. М., 2006.
  5. Anttila A, Ronco G, Clifford G, et al. Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer 2004;91:935-41.
  6. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009;199:926-35.
  7. van Ballegooijen M, van den Akker-van Marle E, Patnick J, et al. Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness. Eur J Cancer 2000;36:2177-88.
  8. Clemens J, Brenner R, Rao M, et al. Evaluating new vaccines for developing countries. Efficacy or effectiveness? JAMA 1996;275:390-97.
  9. Clifford GM, Rana RK, Franceschi S, et al. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1157-64.
  10. Derkay CS. Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolayngol Head Neck Surg 1995;121:1386-91.
  11. Garland SM. The Australian experience: benefits from quadrivalent vaccination in real life. Satellite symposium 18thFeb. EUROGIN 2010, Monaco.
  12. Haupt RM. ACIP presentation. 2008.
  13. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007;25:4931-39.
  14. Lacey CJN, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006;24(3):S35-S41.
  15. Srodon M, Stoler MH, Baber GB, et al. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol. 2006; 30:1513-18.
  16. Schiffman M, Solomon D. Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch Pathol Lab Med 2003;127:946-49.
  17. Fleischer AB Jr, Parrish CA, Glenn R, et al. Condylomata acuminata (genital warts): patient demographics and treating physicians. Sex Transm Dis 2001;28:643-47.
  18. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. Lyon, France: IARC Press; 2004. IARC Cancer Base No. 5, Version 2.0
  19. Jansen KU, Shaw AR. Human papillomavirus vaccines and prevention of cervical cancer. Annu Rev Med 2004;55:319-31.
  20. Guimaraes EM, Brasileiro Filho G, Pena SD. Human papillomavirus detection in cervical dysplasias or neoplasias and in condilomata acuminata by in situ hybridization with biotinylated DNA probes. Rev Inst Med Trop Sao Paulo 1992;34(4):309-14.
  21. Handley JM, Maw RD, et al. Anogenital warts in children. Clin Exp Dermatol 1993;18(3):241-47.
  22. Harmsel B, Smedts F, et al. Relationship between human papillomavirus type 16 in the cervix and intraepithelial neoplasia. Obstet Gynecol 1999;93(1):46-50.
  23. Linder J. The ThinPrep Pap Test - Spring 1998 Update. Gen Inf Neop Up 1998;1:16-8.
  24. Londesborough P, et al. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer 1996;69(5):364-68.
  25. Lorincz A, Davies PO. The Hybrid Capture II Assay for the detection of human papillomavirus. Gen Inf Neop Up 1998;1:18-9.
  26. Einstein MH, Baron M, Levin M, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009;5:705-19.
  27. David MP, Van Herck K, Handr K. at al. Long-term persistence of anti-HPV-16 and -18antibodies indused by vaccinacion wich the ASO4-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol 2009,115(Suppl. 3):S1-6.
  28. Munoz N, Manalastas R Jr, Pitissutthum P, et al. Safety, immunogenicity, and efficacy of guadrivalent human papillomavirus (types 6,11.16.18) recombinanant vaccine in women ages 24-45 years: a randomized, double-blind trial. Lancet 2009;373:1949-57.
  29. Wacholder S, Chen BE, Wilcox A, et al. Risk of miscarriage wich bivalent vaccine against humen papillomavirus (HPV) types 16 and 18: pooled analysis of two randomized controlled trials. Br Med J 2010;340:712.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies